Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001172661-25-002203
Filing Date
2025-05-15
Accepted
2025-05-15 15:09:10
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8750
  Complete submission text file 0001172661-25-002203.txt   10500
Mailing Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022
Business Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022 (212) 231-4932
ARMISTICE CAPITAL, LLC (Filed by) CIK: 0001601086 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Subject) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-93211 | Film No.: 25951768
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)